Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo
about
Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells.Olmutinib (HM61713) reversed multidrug resistance by inhibiting the activity of ATP-binding cassette subfamily G member 2 and
P2860
Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 March 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Alectinib (CH5424802) antagoni ...... in vitro, in vivo and ex vivo
@en
Alectinib (CH5424802) antagoni ...... in vitro, in vivo and ex vivo.
@nl
type
label
Alectinib (CH5424802) antagoni ...... in vitro, in vivo and ex vivo
@en
Alectinib (CH5424802) antagoni ...... in vitro, in vivo and ex vivo.
@nl
prefLabel
Alectinib (CH5424802) antagoni ...... in vitro, in vivo and ex vivo
@en
Alectinib (CH5424802) antagoni ...... in vitro, in vivo and ex vivo.
@nl
P2093
P2860
P356
P1476
Alectinib (CH5424802) antagoni ...... in vitro, in vivo and ex vivo
@en
P2093
Kenneth Kin Wah To
Likun Chen
Yifan Chen
P2860
P2888
P356
10.1038/EMM.2016.168
P577
2017-03-17T00:00:00Z